Eovist
Adenoma
BayerDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Adenoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Folic Acid US Department of Veterans Affairs | Phase 2 | B |
r-5780 Rise Therapeutics LLC | Phase 1 | CC |
S-Adenosyl-L-Methionine Jun Gong, MD | Phase 1 | CC |
BAY-86-4873 Bayer | D |
Same molecule, other indications
Eovist is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →